Amendment No. 1 to Collaboration AgreementCollaboration Agreement • May 4th, 2020 • Epizyme, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 (“Amendment 1”) is made and entered into as of March 10, 2020 (“Amendment 1 Effective Date”) by and between Boehringer Ingelheim International GmbH, a German corporation, with its principal place of business at Binger Strasse 173, 55216 Ingelheim am Rhein, Germany (“BII”) and Epizyme, Inc., a Delaware corporation, with its principal place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139 USA (“Epizyme”).
